Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

Action history

1. 2019-10-29Received in the Senate and Read twice and referred to the Committee on Finance.
2. 2019-10-28The title of the measure was amended. Agreed to without objection.
3. 2019-10-28Motion to reconsider laid on the table Agreed to without objection.
4. 2019-10-28On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 403 - 0 (Roll no. 586).
5. 2019-10-28Considered as unfinished business.
6. 2019-10-28At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
7. 2019-10-28DEBATE - The House proceeded with forty minutes of debate on H.R. 2115.
8. 2019-10-28Considered under suspension of the rules.
9. 2019-10-28Ms. Schakowsky moved to suspend the rules and pass the bill, as amended.
10. 2019-05-21Subcommittee Hearings Held.
11. 2019-04-09Referred to the Subcommittee on Health.
12. 2019-04-08Introduced in House
13. 2019-04-08Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
14. 2019-04-08Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
15. 2019-04-08Referred to the Subcommittee on Health.